Oral Minoxidil (Low Dose) — Supplements
0.625–5 mg/day oral minoxidil for AGA; 2024 JAMA Dermatology RCT confirmed non-inferiority to topical 5%; superior convenience with predictable hypertrichosis and rare cardiovascular effects.
Overview
Low-dose oral minoxidil (LDOM) has emerged as a clinically significant alternative to topical minoxidil for androgenetic alopecia (AGA), driven by superior convenience, better compliance, and avoidance of scalp irritation and contact dermatitis. Minoxidil was originally developed and FDA-approved as an oral antihypertensive (Loniten, 10–40 mg/day) in the 1970s; oral doses used for hair loss (0.625–5 mg/day) are 5–40× lower than antihypertensive doses. The pivotal 2024 RCT (Penha et al., JAMA Dermatology, n=90 men, 24 weeks) directly compared oral minoxidil 5 mg/day to topical minoxidil 5% twice daily — confirming no statistically significant difference in hair density outcomes, with oral minoxidil showing numerical superiority at the vertex (23.4 hairs/cm² advantage, p=0.09). A 2024 meta-analysis (Sobral et al., International Journal of Dermatology, 4 RCTs, n=279) confirmed pooled equivalence in hair density and diameter. The main distinguishing AE profile of LDOM is hypertrichosis (excess facial and body hair growth) in ~90% of women and ~20-40% of men at 5 mg — predictable, dose-dependent, and reversible on cessation. Women typically use 0.625–2.5 mg/day; men 2.5–5 mg/day. Fluid retention and tachycardia occur rarely at hair loss doses but require screening in patients with cardiovascular risk. A 2022 Dermatology and Therapy review of 20 studies confirmed a strong safety profile when patients are appropriately screened.
Indications
- Androgenetic alopecia (AGA) — male and female pattern hair loss
- Compliance-limited patients who cannot consistently apply topical minoxidil
- Patients with scalp irritation, contact dermatitis, or seborrheic dermatitis worsened by topical minoxidil vehicle
- Telogen effluvium and diffuse hair loss
- Alopecia areata (adjunctive, off-label)
Mechanism of Action
Minoxidil sulfate (the active metabolite, formed by SULT1A1 sulfotransferase in follicular cells) opens ATP-sensitive potassium channels in smooth muscle cells of blood vessels and in dermal papilla cells. This causes membrane hyperpolarization and vasodilation — increasing blood flow and nutrient delivery to the hair follicle
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Oral minoxidil (women) | 0.625–2.5 mg | Once daily, morning | Start at 0.625 mg/day (1/4 tablet); uptitrate to 2.5 mg/day after 4-8 weeks if tolerated; higher doses increase hypertrichosis risk significantly in women |
| Oral minoxidil (men) | 2.5–5 mg | Once daily, morning | Most evidence supports 5 mg/day in men; 2.5 mg for those with cardiovascular concerns or hypertrichosis concern |
Safety & Contraindications
- Hypertrichosis (unwanted facial/body hair growth): most common AE; ~90% of women and ~20-40% of men at 5 mg; dose-dependent and fully reversible on discontinuation; major limiting factor for women
- Fluid retention: peripheral edema can occur — screen for pre-existing cardiac, renal, or hepatic disease before initiating; rare at 2.5-5 mg/day in healthy patients
- Tachycardia/palpitations: reflex sympathetic activation from vasodilation — monitor resting heart rate; discontinue if HR consistently >100 bpm at rest
- Blood pressure: LDOM doses (0.625-5 mg) rarely cause clinically significant hypotension in normotensive patients; check baseline BP
- Minoxidil sulfotransferase (SULT1A1) activity predicts response — patients with low sulfotransferase activity ('non-responders', ~30% of population) respond poorly regardless of dose; eyebrow response to minoxidil has been suggested as a surrogate marker
- Do NOT use in pregnancy — minoxidil is Pregnancy Category C; animal teratogenicity at high doses
- Rare: periorbital edema, systolic hypertension rebound on abrupt cessation at higher doses
- Baseline ECG recommended in patients >40 years or with cardiac risk factors